Trial reportCritical care explorations2026
Comparing Clinical Outcomes in Cardiac Surgical Patients Who Receive Sugammadex Versus Placebo: A Prospective Randomized Blinded Controlled Trial.
Trial report in Critical care explorations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo compare the difference in the number of cardiopulmonary bypass surgical patients who receive sugammadex vs. placebo and who meet the Society of Thoracic Surgery early extubation quality benchmark.
designSingle-center, randomized, double-blind, placebo-controlled trial.
settingParticipants were enrolled at a single U.S. hospital between August 2023 and July 2025. PATIENTS: Seventy-four eligible cardiac surgery patients undergoing cardiopulmonary bypass with anticipated institutional fast-track extubation were enrolled; 64 were included in the analysis.
interventionsAdministration of either sugammadex or placebo 15 minutes after arrival to the ICU following cardiac surgery. MAIN OUTCOMES AND MEASURES: The primary outcome was the number of patients meeting the Society of Thoracic Surgery quality benchmark of early extubation in the sugammadex vs. placebo groups. Secondary outcomes encompassed specifics related to clinical outcomes, medication requirements, and nursing perception. MEASUREMENTS AND MAIN
resultsSurgery duration (p = 0.0004), bypass duration (p = 0.0177), and intraoperative blood products (p = 0.0003) were all increased in the sugammadex group. No difference was observed in the primary outcome and 96.9% of patients in both groups were extubated within 6 hours after surgery. However, all patients in the sugammadex group achieved a train of four greater than or equal to 0.9 before extubation compared with only 37.5% of the placebo group (p < 0.0001). The intraoperative dose of rocuronium (mean p = 0.0119; median p = 0.0047) was significantly increased in the sugammadex group. All additional demographics and secondary outcomes were comparable between groups.
conclusionsThis trial found no difference in the number of patients who achieved the early extubation benchmark in the sugammadex vs. placebo groups; however, a significant number of patients in the placebo group had residual neuromuscular weakness as defined by quantitative neuromuscular monitoring. Further studies are required to investigate the implications of the high incidence of quantitative monitoring related weakness in this population without the use of sugammadex.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.